What is Alexandria Real Estate Equities's gross profit margin?

What is the revenue and EPS growth rate for Alexandria Real Estate Equities year over year?

What is the market's earnings forecast for Alexandria Real Estate Equities next quarter?

What were the key takeaways from Alexandria Real Estate Equities’s earnings call?

What were the key takeaways from Alexandria Real Estate Equities's earnings call?

What does Alexandria Real Estate Equities do and what are its main business segments?

What guidance did Alexandria Real Estate Equities's management provide for the next earnings period?

What is Alexandria Real Estate Equities's latest dividend and current dividend yield?

- **Q4 2025 Financial Strength**: FFO of $2.16 per share and $9.01 annually, with 1.2 million sq. ft. leased in Q4, the highest in a year.
- **Occupancy Resilience**: 90.9% occupancy at year-end, up 30 bps, with 2026 guidance of 87.7%-89.3%.
- **Disposition Momentum**: $1.5 billion in Q4 dispositions, with $2.9 billion guided for 2026, 65%-75% in non-core assets.
- **Cost Efficiency**: G&A savings of $51.3 million in 2025, with 2026 savings expected to halve.
- **Strategic Shifts**: Pivot to office use for 4 developments, reducing CapEx by $300 million, and cautious optimism on biotech recovery.
- **Risk Management**: $6 million quarterly headwind from tenant wind-downs, reflecting public biotech sector challenges.


**【CEO Summary Section】**
- Focused on navigating a challenging life science industry landscape, with a strategic emphasis on dispositions, occupancy optimization, and significant reduction of capital expenditures (CapEx).
- Highlighted the completion of $1.5 billion in dispositions across 26 transactions in Q4 2025, achieving the highest quarterly leasing volume in a year (1.2 million sq. ft.).
- Emphasized the importance of maintaining a strong balance sheet and timely execution of the 2026 path forward, including a 2% to 3% assumed benefit from asset sales in the second half of 2026.
- Noted the outperformance of Megacampuses, which represent 78% of annual rental revenue, with occupancy exceeding the broader market by 19%.
- Warned of a temporary decline in occupancy in Q1 2026 due to 1.2 million sq. ft. of key lease expirations, but expressed confidence in second-half recovery driven by signed leases expected to commence in Q3 2026.

**【CFO Financial Commentary】**
- Reported FFO per share diluted as adjusted of $2.16 for Q4 2025 and $9.01 for the full year, aligning with the midpoint of prior guidance.
- Leasing volume for Q4 2025 was 14% higher than the prior quarter average and 10% above the trailing 8-quarter average, with 393,000 sq. ft. of vacant space leased, nearly double the quarterly average over the past 5 quarters.
- Occupancy reached 90.9% at year-end, up 30 basis points from Q3 2025, with guidance for 2026 occupancy ranging between 87.7% and 89.3%.
- Same-property NOI decreased 6% on a cash basis for Q4 2025, but full-year results met the midpoint of prior guidance, driven by occupancy declines and free rent burn-off.
- Highlighted G&A cost savings of $51.3 million (30%) in 2025, with expectations for annual savings in 2026 to be roughly half of 2025 levels.
- Capitalized interest for 2026 was guided to $250 million, down 24% from 2025, reflecting reduced construction activity.

**【Q&A Highlights】**
- **Leasing Momentum**: Q4 2025 leasing volume was the highest in a year, with 13% of key expiring spaces in early-stage negotiations and 40% identified for potential prospects. However, free rent and rental rate pressure remained significant.
- **Disposition Strategy**: 2026 dispositions are expected to total $2.9 billion, with 65%-75% allocated to non-core assets and land. The weighted-average closing date for dispositions is expected to be Q3 2026.
- **Tenant Wind-Down Risks**: A $6 million quarterly headwind from tenant wind-downs was noted, driven by public biotech sector challenges and clinical trial failures.
- **Development Pivot**: Four development projects were pivoted to office use, reducing future funding needs by $300 million and reflecting a strategic shift toward more stable income streams.
- **Regulatory Impact**: The FDA's focus on accelerating approvals and the broader life science industry's recovery timeline (2-3 years for core markets, 4-5 years for tertiary markets) were discussed, with cautious optimism about JPMorgan's positive sentiment on potential IPOs.
- **Stock Performance**: The 19% year-to-date stock rally was attributed to NAV re-rating and value-driven investors, with buybacks not yet on the agenda due to disposition program priorities.


Alexandria Real Estate Equities, Inc. (ARE) Q4 2025 Earnings Call Transcript

- **Megacampus Focus**: 77% of ARR from megacampuses, with plans to reduce non-income-producing assets to 10-15% of portfolio.
- **Financial Performance**: Q3 FFO per share of $2.22, down 6% YoY, driven by 110 bps occupancy decline.
- **Leasing Strength**: 1.2 million sq. ft. leased in Q3, 82% from existing tenants, with 15.2% rental rate growth on renewals.
- **Risk Management**: $685 million potential impairments on non-core assets, with 2026 expiring leases totaling $46 million in annual rent.

**【CEO Summary Section】**
- Emphasized the company's mission to enable life science innovation, despite challenges like government shutdowns and a slow biotech recovery.
- Highlighted the strategic focus on megacampuses, with 77% of ARR from these assets, aiming to reduce non-income-producing assets to 10-15% of the portfolio.
- Noted the importance of regulatory clarity and cost control in the biotech industry.

**【CFO Financial Commentary】**
- Reported Q3 FFO per share as adjusted of $2.22, down 6% year-over-year due to lower occupancy and venture gains.
- Occupancy declined to 90.6%, with 110 basis points of apples-to-apples decline, driven by oversupply in certain submarkets.
- Leasing volume of 1.2 million sq. ft. remained solid, with 82% from existing tenants and 15.2% rental rate growth on renewals.
- G&A expenses reduced by $49 million annually, with a 5.7% G&A/NOI ratio, outperforming peers.
- Capitalized interest expected to decline in 2026 as development pipeline is curtailed.

**【Q&A Highlights】**
- 2026 outlook includes $1.2 billion in expiring leases, with 1.2 million sq. ft. of known move-outs, and potential impairments of $685 million on non-core assets.
- Dividend policy under review for 2026, with focus on reducing leverage and retaining cash for construction commitments.
- Strategy to pivot non-core assets to alternative uses (e.g., residential) to capitalize on resi demand.
- Regulatory delays (FDA shutdown) and capital market challenges (high interest rates) cited as key risks to demand recovery.

Alexandria Real Estate Equities (ARE)-28 Oct 25-2025 Q3 Earnings call transcript

- **Record Lease Achievement**: Secured largest-ever 466,000 sq ft pharma lease, underscoring Megacampus strategy success.
- **Development Momentum**: 218,000 sq ft delivered with 90%+ lease-up, 6.6% yield, and 131,768 sq ft in pipeline leasing.
- **Asset Recycling Progress**: $785M in dispositions YTD targeting 7.5-8.5% cap rates, with 52% of pipeline in unstabilized properties.
- **Financial Resilience**: 6.3% G&A as a % of NOI (lowest in 10 years), $4.6B liquidity, and 12-year debt maturity.
- **Risks**: Occupancy at 90.8% (down 90bps QoQ), same-property NOI decline, and elevated free rent in Q2.

**【CEO & Executive Chairman Summary】**
- Secured the largest lease in company history (466,000 sq ft) with a top-20 pharma tenant at Campus Point, San Diego, reflecting strategic Megacampus positioning and tenant demand for R&D hubs.
- Highlighted progress on the 2027+ stabilization pipeline, including 311 Arsenal, Sylvan Road, 1450 Owens, and 701 Dexter, with $1.1B in executable asset sales pipeline.
- Advocated for Fed rate cuts to support capital markets and expressed optimism about FDA efficiency improvements under Commissioner Marty Makary.

**【Hallie Kuhn - Life Science Industry Update】**
- Private biotech accounted for 30% of Q2 leasing, driven by later-stage venture funding ($22B YTD) and disciplined tenant expansion.
- Public biotech leasing (24%) was dominated by new leases, with M&A activity up 2025 YTD vs. full 2024, signaling capital recycling.
- Biomedical institutions (22%) maintained demand despite NIH funding uncertainty, with 80% of NIH grants supporting external research.
- Large pharma (5%) focused on strategic R&D expansion, exemplified by the Campus Point lease.

**【Peter Moglia - Development & Asset Recycling】**
- Delivered 218,000 sq ft of Class A+ lab space with 90%+ lease-up, achieving 6.6% initial yield (100bps improvement at One Alexandria Square).
- Q2 leasing of 770,000 sq ft included 131,768 sq ft in development/redevelopment, with 9.4-year average lease duration.
- Competitive supply in key markets (Boston, SF, San Diego) remains constrained, with 2026 deliveries 67% pre-leased.
- Asset recycling program: $84M in Q2 sales, $785M total dispositions YTD targeting 7.5-8.5% cap rates, with 52% of pipeline in unstabilized properties.

**【Marc Binda - Financial Performance】**
- FFO per share: $2.33 (1.3% QoQ increase), driven by development deliveries.
- Occupancy: 90.8% (down 90bps QoQ), guided to 90.9-92.5% by year-end.
- Same-property NOI: -5.4% YoY (cash basis), with pressure expected to continue due to lease roll expirations.
- G&A expenses: 6.3% of NOI (lowest in 10 years), with $49M annual savings target.
- Balance sheet: $4.6B liquidity, 12-year average debt maturity, and 5.2x leverage target.

**【Q&A Highlights】**
- **Lease Execution**: The pharma tenant chose Campus Point for its Megacampus amenities, infrastructure (e.g., vibration requirements), and proximity to talent pools.
- **Free Rent Trends**: Elevated free rent in Q2 due to one large lease, but uncertain if peak has been reached.
- **Occupancy Outlook**: 2025 year-end guidance assumes 2% benefit from asset sales, with 2026 expirations under active evaluation.
- **FDA Impact**: Tenants vary in concern levels, with clinical-stage companies most sensitive to FDA delays.
- **Capital Allocation**: Prioritizing Megacampus ownership overJV transactions, with potential to monetize equity in core assets if needed.

Alexandria Real Estate Equities, Inc. (ARE) Q2 2025 Earnings Call Transcript

- **Fortress Balance Sheet**: 12.2-year debt maturity, 5.2x leverage, top 10% credit rating.
- **Leasing Strength**: 1.03M sq ft leased Q1, 18.5% renewal rate, 75% pipeline pre-leased.
- **Tariff Resilience**: 10% tariff on materials reduces yields by 2.5-3.5bps, minimal impact on 2025 NOI.
- **Regulatory Risk**: FDA, NIH restructuring could delay approvals, but innovation pipeline remains strong.
- **Asset Recycling**: $610M/YTD dispositions, 31% of 2025 guidance, with 75% land sales accretive.
- **Financial Discipline**: 6.9% G&A/NOI (vs. 10% industry avg), 57% dividend payout ratio.


**【Joel Marcus Opening Remarks】**
- Alexandria is the first and only pure-play life science REIT, owning 40M sq ft of high-quality assets with 75% of rental revenue from mega campuses.
- The company has a fortress balance sheet with top 10% credit rating, 12.2-year average debt maturity, and 5.2x leverage target.
- 2025 Q1 collections at 99%, with 89% of leasing activity from existing tenants.
- Regulatory challenges (FDA, NIH) and macroeconomic headwinds (interest rates, tariffs) are top risks, but innovation pipeline remains strong.

**【Hallie Kuhn Tenant Base & Leasing Update】**
- Q1 2025 leasing: 1.03M sq ft, 18.5% cash renewal rate, 7.5% release rate, 10.1-year WALT.
- Tenant mix: 51% investment grade, 87% top 20 tenants are large caps.
- Key segments: public biotech (27%), multinational pharma (13%), private biotech (12%).
- Mega campus strategy: 75% of pipeline pre-leased, 75% of 2025-26 NOI from development.

**【Peter Moglia Development & Asset Recycling】**
- Q1 2025 delivered 309K sq ft (100% leased), with $37M annual NOI. 1.6M sq ft pipeline (75% pre-leased) to add $171M NOI by 2026.
- Tariffs impact: 10% tariff on construction materials would reduce yields by 2.5-3.5bps.
- Asset recycling: $610M in dispositions/YTD, including $124M land sale in San Diego.
- Competitive supply: 2025 deliveries down 40% YoY, 2026 deliveries at 46% pre-leased.

**【Marc Binda Financial Highlights】**
- Q1 2025: $2.30 FFO per share (down 7% YoY), 5% adj. EBITDA growth, 71% EBITDA margin.
- G&A savings: $49M YoY, 6.9% of NOI (vs. 10% industry avg).
- Capitalized interest: $4.1B future land bank, $20M reduction in 2025 guidance.
- Dividends: 57% payout ratio, 5.7% yield.
- 2025 FFO guidance: $9.26 (midpoint), 27% 5-year CAGR.

**【Q&A Key Themes】**
- **Leasing Momentum**: Private biotech funding steady, but boards remain cautious. 2025 pipeline 75% pre-leased.
- **Tariffs Impact**: Minimal dilution to 2025 pipeline, but long-term onshoring benefits for biomanufacturing.
- **Regulatory Risk**: FDA, NIH restructuring could delay approvals, but private sector filling R&D gap.
- **Disposition Progress**: $610M/YTD, 31% of $1.95B guidance, with strong demand for land and non-core assets.
- **Capital Allocation**: Prioritize development pipeline over buybacks, but open to opportunistic share repurchases.


Alexandria Real Estate Equities (ARE)-29 Apr 25-2025 Q1 Earnings call transcript

- **Resilient Growth**: 6% FFO per share growth in tough macro environment, with 90% of 2025 pipeline pre-leased.
- **Life Sciences Catalysts**: Regulatory reforms and J&J $14.6B acquisition highlight sector momentum; expect biotech rebound post-Fed rate cuts.
- **Pipeline Strength**: 2025 pipeline 90% pre-leased; 2026+ shows new submarket activity despite South San Francisco challenges.
- **Balance Sheet Flexibility**: $1.2B liquidity, disciplined capital recycling, and well-covered dividend growth.
- **Strategic Vision**: Proven track record of turning contrarian bets (e.g., Mission Bay) into decade-long growth engines.


**【Executive Chairman Joel Marcus Opening Remarks】**
- **Resilience Amid Crisis**: Team demonstrated remarkable strength during California wildfires, with company supporting recovery efforts despite inadequate local government preparation.
- **Financial Performance**: Achieved 6% FFO per share growth YoY, driven by strong leasing activity (90% of 2025 pipeline pre-leased) and disciplined capital recycling.
- **Industry Outlook**: Optimistic on life sciences sector due to regulatory reforms (e.g., FTC crackdown on middlemen, potential IRA tax repeal), expecting normalized bull market post-Fed rate cuts.
- **Pipeline Strength**: 2027+ pipeline shows new submarket activity; South San Francisco remains slow but rollover leasing progress is strong.
- **Strategic Focus**: Mega-campus development, non-core asset disposition, and maintaining balance sheet flexibility with $1.2B liquidity.

**【Hallie Kuhn Life Sciences Update】**
- **Tenant Success Story**: Highlighted Intracellular Therapeutics' $14.6B acquisition by J&J, showcasing Alexandria's ability to incubate high-impact life sciences companies.
- **Sector Momentum**: Despite biotech macro challenges, other sectors driving leasing demand; expect biotech rebound as Fed rates ease.
- **Pipeline Visibility**: 2025 pipeline 90% leased or under LOI, with 2026+ showing strong activity across submarkets.

**【Capital Recycling & Balance Sheet】**
- **Land Bank Optimization**: Shrinking land bank to focus on mega-campuses; non-core asset sales progressing well.
- **Dividend Strength**: Increasing and well-covered dividend, reflecting financial stability.

**【Historical Perspective】**
- **Cycle Navigation**: Management team successfully navigated three major market cycles, turning Mission Bay/Cambridge land into decade-long growth engines.
- **Contrarian Success**: Defied legacy pundits who urged asset sales during 2009 crisis, proving long-term vision.


Alexandria Real Estate Equities (ARE)-28 Jan 25-2024 Q4 Earnings call transcript

Alexandria Real Estate Equities (ARE)-22 Oct 24-2024 Q3 Earnings call transcript

Alexandria Real Estate Equities (ARE)-23 Jul 24-2024 Q2 Earnings call transcript

Alexandria Real Estate Equities, Inc. (ARE) Q1 2024 Earnings Call Transcript

Alexandria Real Estate Equities, Inc. (ARE) Q4 2023 Earnings Call Transcript

Alexandria Real Estate Equities (ARE)-24 Oct 23-2023 Q3 Earnings call transcript

Alexandria Real Estate Equities (ARE)-25 Jul 23-2023 Q2 Earnings call transcript

Alexandria Real Estate Equities (ARE)-25 Apr 23-2023 Q1 Earnings call transcript

Alexandria Real Estate Equities (ARE)-25 Oct 22-2022 Q3 Earnings call transcript

Alexandria Real Estate Equities (ARE)-27 Jul 22-2022 Q2 Earnings call transcript

Alexandria Real Estate Equities (ARE)-26 Apr 22-2022 Q1 Earnings call transcript

Alexandria Real Estate Equities (ARE)-1 Feb 22-2021 Q4 Earnings call transcript

Alexandria Real Estate Equities (ARE)-27 Oct 21-2021 Q3 Earnings call transcript

Alexandria Real Estate Equities (ARE)-27 Jul 21-2021 Q2 Earnings call transcript

Alexandria Real Estate Equities (ARE)-27 Apr 21-2021 Q1 Earnings call transcript

Alexandria Real Estate Equities (ARE)-3 Feb 21-2020 Q4 Earnings call transcript

Alexandria Real Estate Equities (ARE)-27 Oct 20-2020 Q3 Earnings call transcript

Alexandria Real Estate Equities (ARE)-28 Jul 20-2020 Q2 Earnings call transcript

Alexandria Real Estate Equities (ARE)-28 Apr 20-2020 Q1 Earnings call transcript

Alexandria Real Estate Equities (ARE)-29 Oct 19-2019 Q3 Earnings call transcript

Alexandria Real Estate Equities (ARE)-30 Jul 19-2019 Q2 Earnings call transcript

Alexandria Real Estate Equities (ARE)-30 Apr 19-2019 Q1 Earnings call transcript

Alexandria Real Estate Equities (ARE)-5 Feb 19-2018 Q4 Earnings call transcript

Alexandria Real Estate Equities (ARE)-30 Oct 18-2018 Q3 Earnings call transcript

Alexandria Real Estate Equities (ARE)-31 Jul 18-2018 Q2 Earnings call transcript

Alexandria Real Estate Equities (ARE)-1 May 18-2018 Q1 Earnings call transcript

Alexandria Real Estate Equities (ARE)-30 Jan 18-2017 Q4 Earnings call transcript

Alexandria Real Estate Equities (ARE)-31 Oct 17-2017 Q3 Earnings call transcript

Actual												0.14	1.82	0.63	3.26	0.04	2.61	0.67	0.47	-0.96	1.67	0.7	0.49	0.44	0.51	0.13	-0.54	0.89	0.25	0.96	-0.38	-0.07	-0.64	-1.38	2.16
Forecast												0.6392	0.4676	0.756	0.5887	0.5396	0.5882	0.5415	0.5314	0.7514	0.6047	1.0284	0.6076	0.6707	0.3879	1.1434	0.5933	0.8668	0.8719	0.8843	0.9217	0.697	0.5904	0.4963	0.28	0.149
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-78.10%	+289.22%	-16.67%	+453.76%	-92.59%	+343.73%	+23.73%	-11.55%	-227.76%	+176.17%	-31.93%	-19.35%	-34.40%	+31.48%	-88.63%	-191.02%	+2.68%	-71.33%	+8.56%	-141.23%	-110.04%	-208.40%	-378.06%	+671.43%	0.00%

Actual	--	--	--	--	--	--	--	--	--	--	--	437.61M	435.86M	543.41M	461.33M	478.69M	508.37M	546.53M	574.66M	612.55M	640.96M	656.85M	665.67M	687.95M	704.34M	707.53M	742.64M	755.55M	755.16M	775.74M	763.25M	743.17M	737.28M	735.85M	728.87M	--
Forecast	--	--	--	--	--	--	--	--	--	--	--	377.42M	441.10M	450.55M	461.67M	482.27M	501.73M	531.53M	547.87M	583.77M	630.88M	652.84M	633.14M	678.19M	700.22M	720.81M	744.00M	761.00M	771.76M	769.21M	774.76M	747.80M	745.29M	751.57M	739.90M	684.78M
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+15.95%	-1.19%	+20.61%	-0.07%	-0.74%	+1.32%	+2.82%	+4.89%	+4.93%	+1.60%	+0.61%	+5.14%	+1.44%	+0.59%	-1.84%	-0.18%	-0.72%	-2.15%	+0.85%	-1.49%	-0.62%	-1.08%	-2.09%	-1.49%	0.00%

ARE

ARE fundamentals

ARE Q1 2026 Earnings Preview

Earnings Call

You can ask Aime

ARE

ARE fundamentals

ARE Q1 2026 Earnings Preview

Earnings Call

ARE Earnings Call Summary for Q1/2026Upcoming2:00 PM on Apr 28, 2026

ARE Earnings Call Summary for Q4/20252:00 PM on Jan 27, 2026

ARE Earnings Call Summary for Q3/20252:00 PM on Oct 28, 2025

ARE Earnings Call Summary for Q2/20252:00 PM on Jul 22, 2025

ARE Earnings Call Summary for Q1/20253:00 PM on Apr 29, 2025

You can ask Aime